. Author manuscript; available in PMC: 2021 May 1.

Published in final edited form as: Breast Cancer Res Treat. 2020 Apr 3;181(1):181–188. doi: 10.1007/s10549-020-05612-7

Table 3.

Frequency of radiation-induced malignancies between LFS and non-LFS patients

	Non-LFS^a		LFS
	n / Median	% / range	n / Median	% / range

BC tumors	7050	-	86^b	-
BC patients	6607	-	51	-
XRT recommended	3898	59%	29	57%
Definitive XRT for BC	3863/3898	99%^**	20/29	69%
XRT in metastatic settings	85/3816^c	3%	2/20	10%
XRT in curative settings	3731/3816^c	97%	18/20	90%
XRT follow up years	4	2–10	12.5	2–20
Post-XRT thyroid cancer	17/3731	0.5%	1/18	6%
Post-XRT sarcoma in radiation field	1/3731	0.03%^*	1/18	6%

Relative risk of thyroid cancer post-XRT^d	N/A		23.82 (95% CI=3.47–163.25, p=0.001) 5.93
Relative risk of sarcoma post-XRT^d	N/A		5.93 (95% CI=0.34–103.04, p=0.22)

LFS, Li Fraumeni Syndrome; BC, breast cancer; XRT, radiation therapy.

The PMCR cohort represents the non-LFS breast cancer patient population seen at Penn Medicine.

Includes primary and recurrent breast tumors

Patients with sufficient data on clinical stage

Relative risk associated with LFS in comparison to the non-LFS cohort in propensity weighted analyses.

p=0.01

^**

p<0.001 by Fisher’s exact test